Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65116 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAHSD17B10ALOX15 | |
| SCHEMBL28422244 | 0.75 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAHSD17B10ALOX15 | |
| SCHEMBL1444159 | 0.73 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10NPSR1ALOX15 | |
| SCHEMBL290478 | 0.73 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL79003 | 0.72 | PKM (0.43) | ALDH1A1LMNAHSD17B10NPSR1ALOX15 | |
| SCHEMBL8971069 | 0.72 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2LMNAHSD17B10ALOX15 | |
| SCHEMBL882685 | 0.70 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2LMNAHSD17B10NPSR1 | |
| SCHEMBL9218455 | 0.70 | ALDH1A1 (0.34) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL12507040 | 0.70 | MMP8 (0.36) | ALDH1A1SMN1; SMN2LMNAHSD17B10NPSR1 | |
| SCHEMBL12507253 | 0.70 | MMP8 (0.36) | ALDH1A1SMN1; SMN2LMNAHSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618292-B2 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1711487-A1 | DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF | Nereus Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20060223822-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | BEYONDSPRING PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060223823-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060217553-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-7064201-B2 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050197344-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | BEYONDSPRING PHARMACEUTICALS, INC. | 2005-09-08 | — | — | US | disclosed |
| WO-2005077940-A1 | DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1529044-A2 | DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF | Nereus Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20050090667-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | BEYONDSPRING PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2004054498-A2 | DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223822-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | TPD52L2, DHPS, DCXR | ALDH1A1 31/4885SMN1; SMN2 4771/4885LMNA 4184/4885 |
| US-20060223823-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | TPD52L2, DHPS, DCXR | ALDH1A1 31/4885SMN1; SMN2 4771/4885LMNA 4184/4885 |
| US-20060217553-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | TPD52L2, DHPS, DCXR | ALDH1A1 31/4885SMN1; SMN2 4771/4885LMNA 4184/4885 |
| US-20050090667-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | TPD52L2, DHPS, DCXR | ALDH1A1 31/4885SMN1; SMN2 4771/4885LMNA 4184/4885 |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | MKI67, HPGDS, HCCS | ALDH1A1 901/4885SMN1; SMN2 4198/4885LMNA 1788/4885 |
| US-20050197344-A1 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | DHFR, DHPS, QDPR | ALDH1A1 32/4885SMN1; SMN2 4699/4885LMNA 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.